Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Covington
Fuji
Mallinckrodt
Teva
QuintilesIMS

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,039,800

« Back to Dashboard

Which drugs does patent 10,039,800 protect, and when does it expire?

Patent 10,039,800 protects QBRELIS and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 10,039,800
Title:Lisinopril formulations
Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Inventor(s): Mosher; Gerold L. (Kansas City, MO), Miles; David W. (Kansas City, MO)
Assignee: SILVERGATE PHARMACEUTICALS, INC. (Greenwood Village, CO)
Application Number:15/805,934
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,039,800
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,039,800

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING HYPERTENSION ➤ Sign Up
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF HYPERTENSION ➤ Sign Up
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION ➤ Sign Up
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ACUTE MYOCARDIAL INFARCTION ➤ Sign Up
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATMENT OF HEART FAILURE ➤ Sign Up
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MYOCARDIAL INFARCTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 10,039,800

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 3003274 ➤ Sign Up
China 108472252 ➤ Sign Up
European Patent Office 3368012 ➤ Sign Up
Japan 2018533583 ➤ Sign Up
South Korea 20180069907 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2017075368 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Covington
McKinsey
Express Scripts
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.